N/A N=34 RESP-FIT: Technology-Enhanced Self-Management in COPD
COPD
Primary: Intervention Feasibility (Number of Participants Who Adhered to Treatment) — 13; 14 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=468 Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab
Breast Cancer · Cardiac Toxicity
Primary: Number of Participants With Trastuzumab-Induced Cardiotoxicity After 52 Weeks of Treatment — 45; 43; 46 Participants
N/A N=51 Metacognitive Training to Enhance Strategy Use in Blast-Related TBI
Brain Concussion · Blast Injuries
Primary: Computerized Tower Of London (cTOL) — 24.6; 25.1; 21.7; 24.7 Seconds — p=0.0004
Phase 2 N=25 SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients
Kidney Cancer Metastatic · Kidney Cancer · Kidney Cancer, Stage IV
Primary: Number of Participants With Treatment-related Adverse Events Grade 3 or Higher as Assessed by CTCAE v4.0 — 9 Participants
N/A N=14 Digital Self-Management and Health Coaching for Type 2 Diabetes - Impact on Diabetes Clinical and Wellness Indicators
Diabetes Mellitus, Type 2
Primary: HbA1C Value at 3 Months From Subject Start of Study Compared to Baseline — 8.2 percentage of HBA1C in blood
Phase 2 N=22 Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss
Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss
Primary: Number of Participants With Adverse Events — 3; 6; 4; 3 Participants
Phase 1 N=12 Evaluate the Infectivity Equivalence of Current and New Lots of Plasmodium Falciparum Strain NF54
Malaria,Falciparum
Primary: To Characterize the Infectivity of a New Lot of Plasmodium Falciparum Strain 3D7 Developing Parasitemia Within the Standard WRAIR CHMI Model. — 0; 1; 5; 5 Participants
Phase 2 N=93 An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)
Migraine Headaches
Primary: Number of Participants Free From Headache Pain at 2 Hours After the First Dose of Study Medication Taken for a Migraine Attack With Moderate to Severe Headache Pain…
Phase 2 N=18 Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)
Bacteremia · Soft Tissue Infections · Skin Diseases, Infectious
Primary: Percentage of Participants With an Adverse Event — 55.6 Percentage of Participants
Phase 3 N=272 A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus
Type 1 Diabetes
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 Noninferior to Lantus®) — -0.20; -0.08 Percentage of HbA1c
N/A N=771 VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture (VITAL)
Bone Density · Body Composition · Bone Health
Primary: Change in Bone Density — 1.02; 1.02; 1.02; 1.02 g/cm^2
Phase 2 N=3 Rapalogues for Autism Phenotype in TSC: A Feasibility Study
Tuberous Sclerosis Complex · Self-injury · Autism
Primary: Number of Participants With Compliance to the Treatment Protocol. — 100; 58; 58 percentage of completed visits/measures
Phase 2 N=292 Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis
Atopic Dermatitis
Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation — -44.4; -58.3; -64.6; -70.1 Percent change — p=0.1040
N/A N=20 Effects of Neuromodulation and Rehabilitation of the Locomotor Network in Freezing of Gait
Parkinson Disease With Freezing of Gait
Primary: Change in Functional Connectivity to the Supplementary Motor Area. — -.176; .190 z-score
Phase 1 N=75 A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)
Schizophrenia
Primary: The Number of Participants Who Experienced One or More Adverse Events (AEs) — 5; 3; 4; 5 Participants